Cite
HARVARD Citation
Korjian, S. et al. (2019). Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial. European heart journal. 8 (2), pp. 186-193. [Online].